(Q47789519)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

review article

1 reference

title

Towards personalized, tumour-specific, therapeutic vaccines for cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1 reference

Zhuting Hu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Patrick A Ott

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

Catherine J Wu

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

publication date

11 December 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Immunology

6 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

page(s)

168-182

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

6 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Haematological malignancies: at the forefront of immunotherapeutic innovation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Advances in Therapeutic Cancer Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Adoptive immunotherapy for cancer: harnessing the T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Adoptive cell transfer as personalized immunotherapy for human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Engineered T cells: the promise and challenges of cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Emerging Opportunities and Challenges in Cancer Immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Combination immunotherapy: a road map.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Mutant MHC class II epitopes drive therapeutic immune responses to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Cancer Neoantigens and Applications for Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Oncology meets immunology: the cancer-immunity cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Elements of cancer immunity and the cancer-immune set point

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Cross-presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Tumour heterogeneity and cancer cell plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Clonal evolution in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

A listing of human tumor antigens recognized by T cells: March 2004 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Translating tumor antigens into cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

5T4 oncofoetal antigen: an attractive target for immune intervention in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Therapeutic cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

HLA-binding properties of tumor neoepitopes in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Targeting neoantigens to augment antitumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Molecular and genetic properties of tumors associated with local immune cytolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Immunogenicity of somatic mutations in human gastrointestinal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Expression of tumour-specific antigens underlies cancer immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Exploiting the mutanome for tumor vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Therapeutic vaccines for cancer: an overview of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Roles of heat-shock proteins in innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Heat shock protein vaccines against glioblastoma: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

A Toll-like receptor recognizes bacterial DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

DNA vaccine for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

DNA vaccines for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Talimogene Laherparepvec for the Treatment of Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Cancer immunotherapy via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Dendritic cells: specialized and regulated antigen processing machines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Agonistic CD40 antibodies and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Key roles of adjuvants in modern vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Liposomes as carriers of antigens and adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Designer vaccine nanodiscs for personalized cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Influenza virosomes as vaccine adjuvant and carrier system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Oncogenic cancer/testis antigens: prime candidates for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Signatures of mutational processes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

21 January 2018

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

An immunogenic personal neoantigen vaccine for patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Personal neoantigen cancer vaccines: The momentum builds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

T cell antigen receptor recognition of antigen-presenting molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Development and function of dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Dendritic cell and antigen dispersal landscapes regulate T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Developments in cancer vaccines for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

The multifaceted role of CD4(+) T cells in CD8(+) T cell memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

MHC class II epitope predictive algorithms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Evolving synergistic combinations of targeted immunotherapies to combat cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

A fully automated flow-based approach for accelerated peptide synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Epitope landscape in breast and colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Neoantigen landscape dynamics during human melanoma-T cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI.2017.131

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

31 March 2020

1 reference

12 December 2020

Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha

1 reference

12 December 2020

The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus).

1 reference

12 December 2020

Mechanism of immunopotentiation and safety of aluminum adjuvants.

1 reference

12 December 2020

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRI.2017.131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29226910%20AND%20SRC:MED&resulttype=core&format=json

6 April 2020

PubMed publication ID

29226910

1 reference